{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:26:41Z","timestamp":1792207601609,"version":"4.4.0"},"reference-count":46,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017239","name":"BeiGene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017239","name":"BeiGene.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2025,1,28]]},"DOI":"10.1080\/10428194.2024.2416577","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T08:01:39Z","timestamp":1729756899000},"page":"240-249","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed\/refractory marginal zone lymphoma"],"prefix":"10.1080","volume":"66","author":[{"given":"Catherine","family":"Thieblemont","sequence":"first","affiliation":[{"name":"APHP, H\u00f4pital Saint-Louis, Hemato-oncologie, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3566-8847","authenticated-orcid":false,"given":"Bj\u00f6rn E.","family":"Wahlin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Mohseninejad","sequence":"additional","affiliation":[{"name":"BeiGene Switzerland GmbH, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijun","family":"Wang","sequence":"additional","affiliation":[{"name":"BeiGene USA, Inc, San Mateo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Zhang","sequence":"additional","affiliation":[{"name":"PRECISIONheor, Oakland, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Keeping","sequence":"additional","affiliation":[{"name":"PRECISIONheor, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[{"name":"BeiGene USA, Inc, San Mateo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier L.","family":"Zinzani","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d and Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.010"},{"key":"e_1_3_4_3_1","unstructured":"Swerdlow SH Campo E Harris NL et. al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer. 2017."},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0057"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.754023"},{"key":"e_1_3_4_6_1","unstructured":"Roberts M Tripathy D Martin P. Current Treatment Options in Marginal Zone Lymphoma The American Journal of Hematology\/Oncology. 2017;13(5)."},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_3_4_8_1","unstructured":"European Medicines Agency. Medicines: Imbruvica; 2023 [updated 2023 Sept 22; cited 2023 Dec 7]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imbruvica"},{"key":"e_1_3_4_9_1","unstructured":"European Medicines Agency. Medicines: Brukinsa; 2023 [updated 2023 Sept 29; cited 2023 Dec 7]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/brukinsa"},{"key":"#cr-split#-e_1_3_4_10_1.1","unstructured":"US Food and Drug Administration. BRUKINSA full prescribing information 2023 [updated 2023 Jan"},{"key":"#cr-split#-e_1_3_4_10_1.2","unstructured":"cited 2024 Mar 4]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213217s007lbl.pdf"},{"key":"#cr-split#-e_1_3_4_11_1.1","unstructured":"U.S Food & Drug Administration. FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma 2024 [updated 2024 Mar 7"},{"key":"#cr-split#-e_1_3_4_11_1.2","unstructured":"cited 2024 Mar 20]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanubrutinib-relapsed-or-refractory-follicular-lymphoma#:\u223c:text=On%20March%207%2C%202024%2C%20the Brukinsa%20will%20be%20posted%20here"},{"key":"#cr-split#-e_1_3_4_12_1.1","unstructured":"Conroy R. FDA requests withdrawal of ibrutinib in US for lymphoma indications 2023 [updated 2023 Apr 11"},{"key":"#cr-split#-e_1_3_4_12_1.2","unstructured":"cited 2023 Dec 7]. Available from: https:\/\/www.cancernetwork.com\/view\/fda-requests-withdrawal-of-ibrutinib-in-us-for-lymphoma-indications"},{"key":"e_1_3_4_13_1","unstructured":"Pharmacyclics LLC.; Withdrawal of Approval of Indications for Mantle Cell Lymphoma and Marginal Zone Lymphoma for IMBRUVICA (ibrutinib) Capsules and Tablets updated 2023 Dec 18; cited 2024 Oct 17]. Federal Register. Available from: https:\/\/www.federalregister.gov\/documents\/2023\/12\/18\/2023-27662\/pharmacyclics-llc-withdrawal-of-approval-of-indications-for-mantle-cell-lymphoma-and-marginal-zone."},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02830"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1704"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006083"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-747345"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003121"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.119"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/81.3.515"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/77.1.147"},{"key":"e_1_3_4_27_1","unstructured":"Phillippo DM Ades AE Dias S et al. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submission to NICE. NICE Decision Support Unit. 2016."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3496"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1337-6"},{"key":"#cr-split#-e_1_3_4_30_1.1","doi-asserted-by":"crossref","unstructured":"Johnson & Johnson. IMBRUVICA\u00ae (ibrutinib) Approved by FDA for Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy. [updated 2017 Jan 19","DOI":"10.1097\/01.COT.0000513328.33415.48"},{"key":"#cr-split#-e_1_3_4_30_1.2","unstructured":"cited 2024 Oct 17]. Available from: https:\/\/www.jnj.com\/media-center\/press-releases\/imbruvica-ibrutinib-approved-by-fda-for-marginal-zone-lymphoma-mzl-patients-who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.46883\/2022.25920956"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00145-5"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.06.002"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.056"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2022.2067526"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000969428.35688.4b"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0285-6"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0838-6"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1013-4"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01504-2"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S309171"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00200-5"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2024.2416577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:24:50Z","timestamp":1737462290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2024.2416577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,28]]}},"alternative-id":["10.1080\/10428194.2024.2416577"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2024.2416577","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-07-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}